Logo image of GRI

GRI BIO INC (GRI) Stock Fundamental Analysis

NASDAQ:GRI - Nasdaq - US3622AW4030 - Common Stock - Currency: USD

1.32  -0.08 (-5.71%)

After market: 1.3 -0.02 (-1.52%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GRI. GRI was compared to 557 industry peers in the Biotechnology industry. The financial health of GRI is average, but there are quite some concerns on its profitability. GRI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GRI has reported negative net income.
In the past year GRI has reported a negative cash flow from operations.
In the past 5 years GRI always reported negative net income.
In the past 5 years GRI always reported negative operating cash flow.
GRI Yearly Net Income VS EBIT VS OCF VS FCFGRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of GRI (-279.02%) is worse than 92.82% of its industry peers.
GRI has a Return On Equity of -935.93%. This is amonst the worse of the industry: GRI underperforms 82.23% of its industry peers.
Industry RankSector Rank
ROA -279.02%
ROE -935.93%
ROIC N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRI Yearly ROA, ROE, ROICGRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRI Yearly Profit, Operating, Gross MarginsGRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

GRI has more shares outstanding than it did 1 year ago.
GRI has more shares outstanding than it did 5 years ago.
GRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRI Yearly Shares OutstandingGRI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
GRI Yearly Total Debt VS Total AssetsGRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.45, we must say that GRI is in the distress zone and has some risk of bankruptcy.
GRI has a Altman-Z score of -21.45. This is amonst the worse of the industry: GRI underperforms 86.36% of its industry peers.
There is no outstanding debt for GRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.45
ROIC/WACCN/A
WACCN/A
GRI Yearly LT Debt VS Equity VS FCFGRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

GRI has a Current Ratio of 1.41. This is a normal value and indicates that GRI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.41, GRI is doing worse than 82.94% of the companies in the same industry.
A Quick Ratio of 1.41 indicates that GRI should not have too much problems paying its short term obligations.
GRI has a worse Quick ratio (1.41) than 82.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
GRI Yearly Current Assets VS Current LiabilitesGRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

GRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.18%, which is quite impressive.
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.85% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.75%
EPS Next 2Y35.74%
EPS Next 3Y23.11%
EPS Next 5Y18.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRI Yearly Revenue VS EstimatesGRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 20K 40K 60K 80K
GRI Yearly EPS VS EstimatesGRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2024 2025 2026 2027 2028 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRI Price Earnings VS Forward Price EarningsGRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRI Per share dataGRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as GRI's earnings are expected to grow with 23.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.74%
EPS Next 3Y23.11%

More info and screens

0

5. Dividend

5.1 Amount

GRI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRI BIO INC

NASDAQ:GRI (6/20/2025, 8:00:02 PM)

After market: 1.3 -0.02 (-1.52%)

1.32

-0.08 (-5.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners0.21%
Inst Owner Change-43.79%
Ins Owners0.02%
Ins Owner Change0%
Market Cap3.10M
Analysts80
Price Target107.1 (8013.64%)
Short Float %5.51%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.96%
Min EPS beat(2)-39.72%
Max EPS beat(2)99.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-46.29%
PT rev (3m)-46.29%
EPS NQ rev (1m)73.04%
EPS NQ rev (3m)73.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-1005.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.57
P/tB 2.57
EV/EBITDA N/A
EPS(TTM)-108.62
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.47
FCFYN/A
OCF(TTM)-3.47
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -279.02%
ROE -935.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-261.48%
ROA(5y)-280.2%
ROE(3y)-1860.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z -21.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.26%
EPS Next Y78.75%
EPS Next 2Y35.74%
EPS Next 3Y23.11%
EPS Next 5Y18.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.43%
EBIT Next 3Y-7.13%
EBIT Next 5Y-8.42%
FCF growth 1Y-50.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.15%
OCF growth 3YN/A
OCF growth 5YN/A